Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

European Research Program with Eleven Institutions from Six Countries In 2023, Merck KGaA, Darmstadt, Germany and Intel announced the joint investment in the academic research program for a period ...

DARMSTADT, Germany — Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world’s largest semiconductor designers and manufacturers, have begun ...

2024--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world’s largest semiconductor designers and manufacturers ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The focus is on the application of Artificial Intelligence for innovations aimed at making semiconductor processes more sustainable DARMSTADT, Germany, November 07, 2024--(BUSINESS WIRE)--Merck KGaA, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...